As cell and gene therapy manufacturing matures, automation has increasingly been applied to core unit operations, while supporting workflows such as media and buffer preparation, formulation management, cryoprotectant handling, and material transfer often remain fragmented and difficult to standardize across products, sites, and operators. As organizations scale, these workflows can become a form of manufacturing technical debt, emerging as hidden bottlenecks that increase complexity, complicate tech transfer, and limit scalability.
 

• As core manufacturing operations become increasingly automated, which supporting workflows are emerging as the biggest constraints on scalability, consistency, or operational efficiency?
• What signals indicate that a support process has reached its automation tipping point, whether through operator burden, deviations, tech transfer challenges, site replication, throughput, or cost?
• How should manufacturers prioritize which support processes to simplify, standardize, digitally enable, automate, or continue managing manually?
• How can manufacturers build enough flexibility across products, formulations, volumes, and sites without creating an overly complex automation strategy?